Active Biotech purchases recently launched Gyrolab Bioaffy
Leanderson continued, "As a biotechnology company focusing on research and development of pharmaceuticals, it is essential that we exploit the most efficient tools available in the market."
Per Sjöberg, Executive Vice President Marketing and Sales, Gyros AB added, "We are extremely pleased that Active Biotech recognizes the value of Gyros technology platform, especially the recently launched Gyrolab Bioaffy. To receive our first order so quickly after commercial introduction in August this year makes us confident that we are on the right track with our product development strategy. We focus on areas in which working in a CD microlaboratory format has clear advantages. Gyrolab Bioaffy allows scientists to assay their proteins under conditions optimized for handling small volumes and many samples. Working at nanoliter scale gives a major reduction in sample and reagent consumption per data point. Since more proteins can be assayed in a single sample, many time-consuming and costly investigations caused by limited sample availability, such as biomarker profiling in small animal models, can be reduced to days rather than weeks."
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.